Department of Oncology and CancerCentreKarolinska at the Karolinska Institute, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden.
J Clin Immunol. 2012 Aug;32(4):855-65. doi: 10.1007/s10875-012-9662-7. Epub 2012 Mar 2.
Previous clinical studies have indicated that natural IgM antibodies have the ability to induce apoptosis of tumor cells but IgE and IgA may also mediate tumor cell killing (in addition to IgG). The aim of the study was to analyse induction of IgM, IgA and IgE antibodies in patients vaccinated with the tumor associated antigen CEA.
Twenty-four resected CRC patients without macroscopic disease were immunized seven times with CEA ± GM-CSF. Four different dose schedules were used over a 12-month period. IgM, IgA and IgE antibody responses against recombinant CEA were determined by ELISA. Patients were monitored immunologically for 36 months and clinically for 147 months.
GM-CSF significantly augmented the anti-CEA response for all three antibody classes. Low dose of CEA tended to induce a higher IgM, IgA or IgE anti-CEA antibody response than higher. Anti-CEA IgA antibodies could lyse CEA positive tumor cells in antibody dependent cellular cytotoxicity (ADCC) as well as in complement dependent cytotoxicity (CDC). A significant correlation between survival and high IgA anti-CEA titers was noted (p = 0.02) irrespective of GM-CSF treatment.
The observation that IgA anti-CEA antibodies were cytotoxic and associated with improved survival might indicate that also these antibodies may exert a clinical anti-tumor effect.
先前的临床研究表明,天然 IgM 抗体具有诱导肿瘤细胞凋亡的能力,但 IgE 和 IgA 也可能介导肿瘤细胞杀伤(除 IgG 外)。本研究旨在分析接种肿瘤相关抗原 CEA 的患者中 IgM、IgA 和 IgE 抗体的诱导情况。
24 例无肉眼疾病的 CRC 患者在 12 个月内接受 7 次 CEA±GM-CSF 免疫接种。使用了四种不同的剂量方案。通过 ELISA 测定针对重组 CEA 的 IgM、IgA 和 IgE 抗体反应。对患者进行了 36 个月的免疫学监测和 147 个月的临床监测。
GM-CSF 显著增强了所有三种抗体类别的抗-CEA 反应。低剂量的 CEA 倾向于诱导更高的 IgM、IgA 或 IgE 抗-CEA 抗体反应,而高剂量的 CEA 则不然。抗-CEA IgA 抗体可在抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性(CDC)中裂解 CEA 阳性肿瘤细胞。无论是否接受 GM-CSF 治疗,均观察到高 IgA 抗-CEA 滴度与生存相关(p=0.02)。
观察到 IgA 抗-CEA 抗体具有细胞毒性并与改善的生存相关,这可能表明这些抗体也可能发挥临床抗肿瘤作用。